Hologic, Inc. (NASDAQ:HOLX) saw a large increase in short interest in the month of May. As of May 31st, there was short interest totalling 8,526,994 shares, an increase of 47.3% from the May 15th total of 5,788,269 shares. Based on an average daily volume of 2,821,047 shares, the days-to-cover ratio is presently 3.0 days. Currently, 3.1% of the shares of the company are sold short.

A number of analysts recently weighed in on HOLX shares. Bank of America Corp cut shares of Hologic from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 15th. Needham & Company LLC raised shares of Hologic from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a research note on Wednesday, February 15th. Zacks Investment Research raised shares of Hologic from a “sell” rating to a “hold” rating in a research note on Friday, February 24th. Jefferies Group LLC reissued a “buy” rating and issued a $49.00 target price (up previously from $46.00) on shares of Hologic in a research note on Monday, March 13th. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $51.00 target price on shares of Hologic in a research note on Tuesday, March 14th. Five equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Hologic has an average rating of “Buy” and an average target price of $47.54.

Hologic (NASDAQ HOLX) opened at 44.67 on Friday. The firm has a market capitalization of $12.51 billion, a price-to-earnings ratio of 16.02 and a beta of 1.10. Hologic has a 12 month low of $32.64 and a 12 month high of $46.05. The stock’s 50 day moving average is $44.20 and its 200-day moving average is $41.56.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, May 10th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.46 by $0.04. The company had revenue of $715.40 million for the quarter, compared to the consensus estimate of $685.24 million. Hologic had a net margin of 11.57% and a return on equity of 27.17%. Hologic’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.47 EPS. Equities analysts anticipate that Hologic will post $2.01 earnings per share for the current fiscal year.

In other news, Director Elaine Ullian sold 9,104 shares of the business’s stock in a transaction dated Monday, April 3rd. The shares were sold at an average price of $42.40, for a total transaction of $386,009.60. Following the transaction, the director now owns 23,810 shares in the company, valued at approximately $1,009,544. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Peter J. Valenti III sold 10,005 shares of the business’s stock in a transaction dated Tuesday, May 30th. The stock was sold at an average price of $43.44, for a total transaction of $434,617.20. Following the transaction, the insider now owns 20,994 shares in the company, valued at approximately $911,979.36. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 118,252 shares of company stock worth $5,158,821. Insiders own 0.79% of the company’s stock.

Several hedge funds have recently bought and sold shares of the company. State Street Corp raised its stake in Hologic by 1.5% in the first quarter. State Street Corp now owns 12,710,718 shares of the medical equipment provider’s stock valued at $540,846,000 after buying an additional 189,572 shares during the last quarter. Victory Capital Management Inc. raised its stake in Hologic by 418.5% in the first quarter. Victory Capital Management Inc. now owns 4,050,824 shares of the medical equipment provider’s stock valued at $172,363,000 after buying an additional 3,269,503 shares during the last quarter. Bank of Montreal Can raised its stake in Hologic by 67.8% in the first quarter. Bank of Montreal Can now owns 3,206,769 shares of the medical equipment provider’s stock valued at $136,448,000 after buying an additional 1,295,885 shares during the last quarter. American Century Companies Inc. raised its stake in Hologic by 229.4% in the first quarter. American Century Companies Inc. now owns 3,164,928 shares of the medical equipment provider’s stock valued at $134,668,000 after buying an additional 2,204,085 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in Hologic by 6.4% in the first quarter. Geode Capital Management LLC now owns 3,116,366 shares of the medical equipment provider’s stock valued at $132,440,000 after buying an additional 186,854 shares during the last quarter. Hedge funds and other institutional investors own 94.09% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Hologic, Inc. (HOLX) Short Interest Update” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/06/11/hologic-inc-holx-short-interest-update.html.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.